Phase 3 N=53 Prevention of Metabolic Complications of Glucocorticoid Excess
Iatrogenic Cushing Disease
Primary: CT Abdomen — 0.08; -0.03 ratio
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=16 Pressure Variability Study
Heart Failure
Primary: Mean Change in Pulmonary Artery Pressure (PAP) Due to Change in Posture — 27.7 mmHg — p=0.429
N/A N=240 Parent Program to Improve Child Behavior Problems
Child Behavior Problems
Primary: Change From Baseline in the Eyberg Child Behavior Inventory (ECBI) Score at Different Time Points (Baseline up to 18 Weeks) — -7; -22; -2; -5 units on a scale
Phase 1 N=80 Effectiveness and Safety of Different Doses of BI 1026706 in Patients With Postoperative Dental Pain
Pain, Postoperative
Primary: SPID0-8h — -50.14; -24.06; -77.54; 124.47 units on scale
Early Phase 1 N=30 Does Intravenous Lactated Ringer Solution Raise Measured Serum Lactate?
Hyperlactatemia
Primary: Change in Mean Lactate Level of the LR Group Compared to the NS Group. — 0.93; 0.37 mmol/L
N/A N=18 W8Loss2Go: mHealth Weight Management Strategy
Obesity
Primary: Body Mass Index (BMI) z -Score — -0.1 z-score
N/A N=17 The EMERGE Project: Feasibility of Assessing Economic and Sexual Risk Behaviors Using Text Messages in Young Adults
Feasibility
Primary: Number of Participants Who Respond to the Survey in Week 1 — 7 Participants
N/A N=114 To Investigate the Impact of a Nutritional Supplement on Bone Turnover Markers in Indian Healthy Premenopausal Women (25- 45 Years) After 6 Months of Intervention
Growth and Development
Primary: Change From Baseline in Serum Cross Linking C-telopeptide of Type 1 Collagen (s-CTX-1) at 6 Months — 0.4440; 0.4410; 0.2828; 0.3245 Micrograms per litres (mcg/L)…
N/A N=128 Inflammation and the Heart
Rheumatoid Arthritis
Primary: Left Ventricular Mass Indexed to BSA, g/m^2 — 43.8; 42.2 g/m^2
Phase 2 N=60 Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer
Prostate Cancer
Primary: Safety, Feasibility and Tolerance of Revlimid as Assessed by Number of Participants Experiencing Grade 3 and 4 Adverse Events. — 3; 10 Participants
N/A N=140 Effectiveness of the Precision Spinal Cord Stimulator System at Sub-Perception Amplitude
Chronic Pain
Primary: Proportion of Subjects With 50% or Greater Reduction in Overall Pain Intensity From Baseline — 32; 41 Participants
Phase 4 N=130 Interventional Study of Active Weight Management in Patients With Type 2 Diabetes and Obesity in Routine Clinical Practice During 12 Months.
Type 2 Diabetes Mellitus (T2DM)
Primary: Number of Patients With Clinically Significant Weight Reduction (>5%) Compared to Baseline at Month 12 — 50; 4; 50; 26 Participants
N/A N=62 Trigeminal Nerve Stimulation for ADHD
Attention Deficit Hyperactivity Disorder (ADHD)
Primary: ADHD-IV Rating Scale (ADHD-RS) — 32.12; 32.83; 26.16; 28.53 score on a scale — p=.54
N/A N=100 Comparing Cetaphil Restoraderm System Versus Standard Skin Care in Infants
Atopic Dermatitis
Primary: Percentage of Participants With Cumulative Atopic Dermatitis Diagnosed by Investigator at 12 Months — 13.2; 25 Percentage of participants
N/A N=21 Donor Human Milk in Neonatal Abstinence Syndrome
Neonatal Abstinence Syndrome
Primary: Percentage of Infants Achieving a GI Subscore >2 Over the Study Period — 39; 61 Percentage of participants — p=0.001